These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38902130)

  • 21. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
    Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
    J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of transcatheter arterial chemoembolization-lenvatinib sequential therapy for patients with unresectable hepatocellular carcinoma: a single-arm clinical study.
    Chen R; Li L; Li Y; Song K; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Jun; 13(3):1367-1375. PubMed ID: 35837188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent hepatogastric fistula during lenvatinib therapy for advanced hepatocellular carcinoma managed by over-the-scope clip closure: a case report.
    Miwa T; Kochi T; Watanabe K; Hanai T; Imai K; Suetsugu A; Takai K; Shiraki M; Katsumura N; Shimizu M
    J Rural Med; 2021 Apr; 16(2):102-110. PubMed ID: 33833836
    [No Abstract]   [Full Text] [Related]  

  • 24. Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature.
    Oura K; Takuma K; Nakahara M; Tadokoro T; Fujita K; Mimura S; Tani J; Morishita A; Kobara H; Masaki T
    Mol Clin Oncol; 2021 Aug; 15(2):154. PubMed ID: 34178325
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus.
    Wu HX; Ding XY; Xu YW; Yu MH; Li XM; Deng N; Chen JL
    World J Gastroenterol; 2024 Feb; 30(8):843-854. PubMed ID: 38516240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
    Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma.
    Xu Y; Fu S; Mao Y; Huang S; Li D; Wu J
    Front Med (Lausanne); 2022; 9():919069. PubMed ID: 36117969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.
    Llovet JM; Real MI; Montaña X; Planas R; Coll S; Aponte J; Ayuso C; Sala M; Muchart J; Solà R; Rodés J; Bruix J;
    Lancet; 2002 May; 359(9319):1734-9. PubMed ID: 12049862
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
    World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and sequential ablation in the treatment of advanced hepatocellular carcinoma.
    Liu Y; Qiao Y; Zhou M; Guo J; Lin Y; Li W; An C; Li C
    Cancer Med; 2023 Mar; 12(5):5436-5449. PubMed ID: 36254376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A case of advanced hepatocellular carcinoma wherein readministration was made possible due to successful transcatheter arterial embolization for intratumoral hemorrhage during Lenvatinib administration].
    Hara H; Nakano Y; Arai K; Kaneko Y; Sakaki K; Fukami Y; Ikemiyagi H; Yoshino K; Sakita S
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(5):476-485. PubMed ID: 35545547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman O; Elsayed Z
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study.
    Yau T; Kaseb A; Cheng AL; Qin S; Zhu AX; Chan SL; Melkadze T; Sukeepaisarnjaroen W; Breder V; Verset G; Gane E; Borbath I; Rangel JDG; Ryoo BY; Makharadze T; Merle P; Benzaghou F; Milwee S; Wang Z; Curran D; Kelley RK; Rimassa L
    Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):310-322. PubMed ID: 38364832
    [TBL] [Abstract][Full Text] [Related]  

  • 34. External beam radiotherapy for unresectable hepatocellular carcinoma.
    Abdel-Rahman O; Elsayed Z
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011314. PubMed ID: 28267205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cotreatment with lenvatinib and warfarin potassium caused prothrombin time prolongation.
    Sasaki Y; Sakamori R; Yamada R; Shigekawa M; Tahata Y; Makino Y; Nakabori T; Kodama T; Hikita H; Tatsumi T; Takehara T
    Hepatol Res; 2019 Nov; 49(11):1357-1361. PubMed ID: 31119866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast growth factor inhibition by molecular-targeted agents mitigates immunosuppressive tissue microenvironment in hepatocellular carcinoma.
    Suzuki H; Iwamoto H; Tanaka T; Sakaue T; Imamura Y; Masuda A; Nakamura T; Koga H; Hoshida Y; Kawaguchi T
    Hepatol Int; 2024 Apr; 18(2):610-622. PubMed ID: 37864726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study.
    Huang J; Wang ZG; Tao QF; Yang Y; Yuan SX; Gu FM; Liu H; Pan ZY; Jiang BG; Lau WY; Zhou WP
    Front Immunol; 2023; 14():1198562. PubMed ID: 37483609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma.
    Ishizaki M; Kaibori M; Matsushima H; Kosaka H; Matsui K; Sekimoto M
    Clin J Gastroenterol; 2021 Dec; 14(6):1700-1705. PubMed ID: 34480729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival benefit from adjuvant TACE combined with Lenvatinib for patients with hepatocellular carcinoma and microvascular invasion after curative hepatectomy.
    Liang L; Xu ZD; Lu WF; Du CF; Gao ZY; Huang XK; Wang KD; Ye TW; Dai MG; Liu SY; Shen GL; Liu JW; Zhang CW; Huang DS
    Asian J Surg; 2024 May; ():. PubMed ID: 38724372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.